Pfizer is an attractive value play, trading at a significant discount despite strong profitability and growth fundamentals ...

Pfizer beats EPS estimates for the 12th quarter. Explore PFE's oncology success, cost-cutting impact, and why it's rated a ...

Pfizer Inc.’s stock rose handily Tuesday after the drug manufacturer said it’s trending toward the higher end of its 2025 profit projections. Pfizer also beat analyst expectations for first ...

Intel Corp. Chief Executive Lip-Bu Tan seems to be making interesting moves early in his tenure, but that doesn’t mean he’ll achieve success easily. The company has missed out on the ...

Pfizer's CEO said tariff uncertainty is hindering the company from making big investments in the US. Albery Bourla said there could be "tremendous investments" in R&D and manufacturing in the US ...

Global pharmaceutical company Pfizer Inc. is donating $750,000 to bolster tribal health care services in Oklahoma, with three Indigenous-operated clinics set to receive funding. The one-time ...

After years of falling Covid treatment sales, lukewarm drug launches and a fizzled out weight-loss play, Pfizer is focusing on cost-cutting and reinvesting in new drug research in hopes that it ...

Other drugmakers are eyeing the market as well. Pfizer (NYSE: PFE) is certainly in that group. However, the company finds itself at a distinct disadvantage after it recently threw in the towel on ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top ...

The Washington Nationals continue to move intriguing talent through their farm system as two top prospects recently got promoted to the next level. Andrew Golden of the Washington Post shared that ...

Irish staff of drug giant Pfizer are waiting to hear whether another round of cost-cutting, announced on Tuesday, will mean more job losses at the group’s Irish operations. Pfizer said it will ...